NTRK1 and neoplasm: Considering that KSR2 appears to act via the MAPK pathway, we tested the effects of KSR2 overexpression on tumor-cell sensitivity to sorafenib, a drug that blocks tumor growth and angiogenesis by targeting both the MAPK pathway and receptor tyrosine kinases.